Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
Merck
Express Scripts
Harvard Business School

Last Updated: June 29, 2022

FERRIPROX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Ferriprox, and when can generic versions of Ferriprox launch?

Ferriprox is a drug marketed by Chiesi and is included in three NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in twenty-seven countries.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the deferiprone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ferriprox

A generic version of FERRIPROX was approved as deferiprone by TARO PHARM INDS LTD on February 8th, 2019.

  Try it Free

Drug patent expirations by year for FERRIPROX
Drug Prices for FERRIPROX

See drug prices for FERRIPROX

Recent Clinical Trials for FERRIPROX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Chiesi Canada CorpPhase 4
Hadassah Medical OrganizationPhase 2/Phase 3
SocraMetrics GmbHPhase 1

See all FERRIPROX clinical trials

Pharmacology for FERRIPROX
Drug Class Iron Chelator
Mechanism of ActionIron Chelating Activity
Anatomical Therapeutic Chemical (ATC) Classes for FERRIPROX
Paragraph IV (Patent) Challenges for FERRIPROX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FERRIPROX Tablets deferiprone 500 mg 021825 1 2016-01-29

US Patents and Regulatory Information for FERRIPROX

FERRIPROX is protected by four US patents and one FDA Regulatory Exclusivity.

Patents protecting FERRIPROX

Delayed release deferiprone tablets and methods of using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Delayed release deferiprone tablets and methods of using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Delayed release deferiprone tablets and methods of using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Liquid formulation for deferiprone with palatable taste
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

FDA Regulatory Exclusivity protecting FERRIPROX

TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FERRIPROX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for FERRIPROX

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chiesi Farmaceutici S.p.A. Ferriprox deferiprone EMEA/H/C/000236
Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
Authorised no no no 1999-08-25
Lipomed GmbH Deferiprone Lipomed deferiprone EMEA/H/C/004710
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.
Authorised yes no no 2018-09-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for FERRIPROX

See the table below for patents covering FERRIPROX around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1116146 See Plans and Pricing
Canada 2722393 FORMULATION LIQUIDE DE DEFERIPRONE DE GOUT AGREABLE (LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE) See Plans and Pricing
Canada 3077514 COMPRIMES DE DEFERIPRONE A LIBERATION RETARDEE ET PROCEDES D'UTILISATION CORRESPONDANTS (DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Medtronic
Colorcon
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.